ClinicalTrials.gg
WithdrawnNCT04943627Updated Oct 5, 2022

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

A Phase 3 interventional study of Balstilimab (BAL) and Topotecan in Advanced Cancer and Metastatic Cervical Cancer, sponsored by Agenus Inc.. Withdrawn at 3 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-05.

Sponsored by Agenus Inc. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Strategic Business Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This Phase 3 trial is an open-label, randomized study with single-agent Balstilimab (BAL) or Investigator Choice (IC) chemotherapy (single-agent gemcitabine, irinotecan, pemetrexed, vinorelbine, or topotecan) in patients with recurrent, persistent, or metastatic cervical cancer who have progressed after receiving platinum based chemotherapy.

Read the detailed description

The purpose of this Phase 3 trial is to demonstrate prolongation of OS in patients treated with BAL as compared to IC chemotherapy.

This Phase 3 trial is an open-label, randomized study with single-agent BAL or IC chemotherapy (single-agent gemcitabine, irinotecan, pemetrexed, vinorelbine, or topotecan) in patients with recurrent, persistent, or metastatic cervical cancer who have progressed after receiving platinum based chemotherapy.

Population:

Patients with recurrent, unresectable, or metastatic cervical cancer who have progressed after receiving at least 1 prior line of platinum-containing chemotherapy with or without bevacizumab.

In this study, > 50% of patients will have received prior treatment with bevacizumab, which will be determined prior to enrollment.

Stratification

  • Histology (squamous cell carcinoma [SCC] vs adenocarcinoma [AC] or adenosquamous carcinoma [ASC])
  • Region of the world (United States or Europe Union or Australia vs other countries)
  • Eastern Cooperative Oncology Group (ECOG) status 0 vs 1

Randomization

  • 2:1, BAL: IC chemotherapy

Approximately 486 patients will be enrolled and randomized with 2:1 allocation between the BAL and IC chemotherapy arms.

02

Conditions studied

  • Advanced Cancer
  • Metastatic Cervical Cancer

Keywords

  • Advanced Cancer
  • Metastatic Cervical Cancer
  • Open-Label
  • Randomized
  • Monotherapy
  • Anti-PD-1
03

In context

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Agenus Inc. is the lead sponsor of 31 studies on the registry; 2 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily agree to participate by giving written .
  2. ≥ 18 years of age.
  3. Diagnosis and prior systemic treatment:

    1. Has recurrent or cervical cancer (SCC, AC, or ASC histology) and has experienced disease progression during or after treatment with a standard platinum based therapy with or without bevacizumab.
    2. Has received at least 1 prior systemic therapy regimen for recurrent, persistent, and/or metastatic cervical cancer.

    Note: Chemotherapy administered in the or neoadjuvant setting, or in combination with radiation therapy, should not be counted as a prior systemic therapy regimen for recurrent, persistent, and/or metastatic cervical cancer.

  4. - based on Investigator assessment.

    a. Radiological evidence of measurable disease on imaging based on v1.1 Note: Patients must have at least 1 "target lesion" to be used to assess response, as defined by RECIST v1.1. Tumors within a previously irradiated field will be designated as "non target" lesions unless progression is documented, or a is obtained to confirm persistence at least 90 days following completion of radiation therapy.

  5. Has a of at least 3 months and an performance status of 0 or 1.
  6. Patients must have sufficient and adequate formalin-fixed tumor tissue sample available that is not older than 3 years; otherwise, a fresh biopsy is required. Archival tissue or fresh biopsy must be from a site not previously irradiated.
  7. Has adequate organ function as indicated by the following laboratory values:

    1. Adequate hematological function defined by ≥ 1.5 × 109/L, count ≥ 100 × 109/L, and stable ≥ 8 g/dL (without transfusions within 1 week before first dose).
    2. Adequate hepatic function based by a total level ≤ 1.5 × the (ULN), (AST) level ≤ 2.5 × ULN, alanine aminotransferase (ALT) level ≤ 2.5 × ULN, alkaline phosphatase (ALP) ≤ 2.5 × ULN, and albumin ≥ 3.0 mg/dL. In the case of hepatic metastases, \< 5 × ULN for AST/ALT and ALP.
    3. Adequate renal function defined as calculated > 40 mL/min or a serum creatinine \< 1.5 × ULN, per institutional standards (creatinine clearance should be calculated per institutional standards).
    4. Adequate coagulation defined by or prothrombin time ≤ 1.5 × institutional upper limit of normal IULN unless the patient is receiving anticoagulant therapy) and activated partial thromboplastin time ≤ 1.5 × IULN (unless the patient is receiving anticoagulant therapy).
    5. Normal thyroid function (thyroid stimulating hormone) whether or not the patient is on supplemental thyroid hormone.
  8. Has no history of another primary except:

    1. Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of study drug and of low potential risk for recurrence.
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    3. Adequately treated carcinoma in situ without evidence of disease.
  9. Women of (WOCP) must have a negative serum pregnancy test at Screening (within 72 hours before first dose of study drug). Non-childbearing potential is defined as (by other than medical reasons):

    1. ≥ 45 years of age and has not menstruated for greater than 1 year.
    2. Definitive pelvic radiation for the treatment of cervical cancer.
    3. Whose status is post hysterectomy, bilateral oophorectomy, or tubal ligation.
    4. WOCP must be willing to use 2 highly effective methods of (defined in the informed consent form) throughout the trial, starting with the Screening Visit through 90 days after the last dose of study drug Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
  10. Is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Is currently participating and receiving study therapy or has participated in a trial of an agent and received study therapy or used an investigational device within 4 weeks before the first dose of treatment.
  2. Has an inadequate period of time prior to first dose of study treatment that is defined as:

    1. Received systemic cytotoxic chemotherapy or biological therapy within 28 days before initiation of study treatment
    2. Received radiation therapy within 28 days before initiation of study treatment, except for palliative bone therapy, which can be received 2 weeks prior to initiation of study treatment
    3. Had major surgery within 4 weeks before initiation of study treatment
  3. Has received prior therapy with:

    a. Any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints) such as anti-programmed cell death protein 1 and antibodies.

  4. Has persisting toxicity related to prior therapy of v5.0 Grade ≥ 1 severity, with the exceptions noted below:

    1. Peripheral neuropathy Grade ≤ 2.
    2. Alopecia Grade ≤ 2.
  5. Is expected to require any other form of systemic or localized antineoplastic therapy while on trial (including maintenance therapy with another agent, radiation therapy, and/or surgical resection).
  6. Has known severe reactions to fully human monoclonal antibodies (NCI CTCAE v5.0 Grade ≥ 3), any history of anaphylaxis, or uncontrolled asthma.
  7. Is receiving systemic ≤ 7 days prior to the first dose of trial treatment or receiving any other form of systemic medication (corticosteroid use on trial for management of immune-related adverse events and/or as a premedication for intravenous [IV] contrast allergies/reactions is allowed). Patients who are receiving daily corticosteroid replacement therapy are an exception to this rule. Examples of permitted therapy are daily prednisone at doses of 5 to 7.5 mg or equivalent hydrocortisone dose and steroid therapy administered by topical, intraocular, intranasal, and/or inhalation routes.
  8. History of central nervous system tumor, (es), and/or carcinomatous meningitis identified either on the baseline brain imaging obtained during the Screening period or identified prior to consent.

    Note: Patients with a history of that have been treated may participate provided they show evidence of stable supra-tentorial lesions at screening (based on 2 sets of brain images, performed ≥ 4 weeks apart, and obtained after the brain metastases treatment). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be minimal and be expected as sequelae from treated lesions. For individuals who received steroids as part of brain metastases treatment, steroids must be discontinued ≥ 7 days prior to the first dose of study drug.

  9. Has active or history of disease that requires systemic treatment within 2 years of the start of study drug (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) Note: Patients with autoimmune conditions requiring hormone replacement therapy or topical treatments are eligible.
  10. Has had an allogeneic tissue/solid organ transplant requiring ongoing immunosuppressive treatment.
  11. Has or had known drug-induced interstitial lung disease, not fully resolved, or has had a history of pneumonitis that has required oral or IV corticosteroids.
  12. Has an active infection requiring IV systemic treatment.
  13. Has known history of (HIV 1/2 antibodies).
  14. Has known untreated / virus (HBV/HCV) or tuberculosis. Active HBV is defined as a known positive hepatitis B surface antigen result. Active HCV is defined as a known positive hepatitis C antibody result and known quantitative HCV RNA results greater than the lower limits of detection of the assay.
  15. Has (ie, active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months before enrollment, unstable angina, congestive heart failure ( Class ≥ II), or serious uncontrolled cardiac arrhythmia requiring medication.
  16. Has other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current trial.
  17. Has known psychiatric or substance use disorders that would interfere with cooperation or compromise participation with the requirements of the trial.
  18. Is legally incapacitated or has limited legal capacity.
  19. Is pregnant or breastfeeding.
  20. Has received a live/attenuated vaccine within 14 days of first dose of study treatment and other vaccines within 48 hours of first dose of study treatment.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Monotherapy with Balstilimab (BAL)

    300 mg IV once every 3 weeks for up to 24 months

    Drug: Balstilimab (BAL)

  • Active comparator
    Monotherapy with Investigator Choice (IC) Chemotherapy per Institutional guidelines

    Topotecan: 1 or 1.25 mg/m\^2 IV on Days 1 to 5, every 21 days or Vinorelbine: 30 mg/m\^2 IV on Days 1 and 8, every 21 days or Gemcitabine: 1000 mg/m\^2 IV on Days 1 and 8, every 21 days or Irinotecan: 100 or 125 mg/m\^2 IV weekly for 28 days, every 42 days or Pemetrexed: 500 mg/m\^2 IV on Day 1, every 21 days

    Drug: Topotecan · Drug: Vinorelbine · Drug: Gemcitabine · Drug: Irinotecan · Drug: Pemetrexed

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival in patients with PD-L1 positive tumors randomized to BAL vs Investigator's Choice chemotherapy

    Hazard Ratio for Overall Survival (OS) by treatment assignment, stratified by histology, region of the world, ECOG PS in all patients with PD-L1 positive tumors

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

  2. Overall survival in all patients randomized to BAL vs Investigator's Choice chemotherapy

    Hazard Ratio for OS by treatment assignment, stratified by histology, region of the world, ECOG PS in all patients

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

Secondary outcomes

  1. Progression-free survival in patients with PD-L1 positive tumors randomized to BAL vs Investigator's Choice chemotherapy

    Hazard Ratio for PFS by treatment assignment, stratified by histology, region of the world, ECOG PS in all patients with PD-L1 positive tumors

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

  2. Progression-free survival in all patients randomized to BAL vs Investigator's Choice chemotherapy

    Hazard Ratio for PFS by treatment assignment, stratified by histology, region of the world, ECOG PS in all patients

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

  3. Objective response rate (ORR) to BAL and to IC chemotherapy in patients with PD-L1 positive tumors

    Proportion, with Wilson confidence intervals, of patients with best overall response (by RECIST 1.1) of PR or CR, among all patients with PD-L1 positive tumors randomized to BAL and to IC chemotherapy.

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

  4. Objective response rate (ORR) to BAL and to IC chemotherapy in all patients' tumors

    Proportion, with Wilson confidence intervals, of patients with best overall response (by RECIST 1.1) of PR or CR, among all patients randomized to BAL and to IC chemotherapy.

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

Other outcomes

  1. Frequency, severity, and duration of treatment-emergent adverse events (TEAEs) and laboratory abnormalities using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Incidence of grade 3+ TEAEs

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

  2. Frequency, severity, and duration of treatment-emergent adverse events (TEAEs) and laboratory abnormalities using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Median duration of grade 3+ TEAE

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

  3. Frequency, severity, and duration of treatment-emergent adverse events (TEAEs) and laboratory abnormalities using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Incidence of serious AEs

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

  4. Frequency, severity, and duration of treatment-emergent adverse events (TEAEs) and laboratory abnormalities using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Incidence of treatment-related TEAEs leading to death

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

  5. Frequency, severity, and duration of treatment-emergent adverse events (TEAEs) and laboratory abnormalities using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Incidence of treatment-related TEAEs leading to treatment discontinuation

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

  6. Frequency, severity, and duration of treatment-emergent adverse events (TEAEs) and laboratory abnormalities using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Median duration of treatment-related grade 3+ AEs

    Time frame: time until observing 234 OS events but no later than 36 months after enrollment of the last patient

  7. To evaluate the PK of BAL - maximum concentration

    Maximum BAL concentration

    Time frame: At the beginning of each Cycle (each cycle is 21 days) through End-of-treatment (EOT) visit (up to 2 years)

  8. To evaluate the PK of BAL - area under the drug concentration-time curve

    Area under BAL concentration-time curve, per dosing cycle

    Time frame: At the beginning of each Cycle (each cycle is 21 days) through End-of-treatment (EOT) visit (up to 2 years)

  9. To evaluate the immunogenicity of BAL and to assess potential impact on study drug exposure and biological activity

    Anti-drug antibodies- incidence of anti-balstilimab antibodies including neutralizing antibodies.

    Time frame: At the beginning of each Cycle (each cycle is 21 days) through 90-Day Safety Follow-up visit (3 months after last dose of BAL)

07

Study locations

3 sites
  • Optimum Research (Southwest Women's Oncology Center)
    Albuquerque, New Mexico 87109, United States
  • Hematology Center after prof. R. Yeolyan
    Yerevan, 0014, Armenia
  • National Center of Oncology named after V.A. Fanarjian
    Yerevan, 0052, Armenia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Oct 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2021
First posted
Jun 29, 2021
StartActual
Aug 2, 2021
Primary completionActual
Oct 22, 2021
CompletionActual
Oct 22, 2021
Last update
Oct 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04943627
Lead sponsor
Agenus Inc.
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Responsible party
Sponsor
First posted
Jun 29, 2021
Start date
Aug 2, 2021
Primary completion
Oct 22, 2021
Completion
Oct 22, 2021
Last update
Oct 5, 2022

Study contacts

Medical Director
study director · Agenus Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Balstilimab

Start the discussion